By Healthcare Edge Editorial Staff
Eterna Therapeutics Inc. (Nasdaq: ERNA), a life science company focused on the potential of mRNA cell engineering, said it appointed Dorothy Clarke to its board of directors.
Dorothy’s extensive experience will continue to help deliver on the promise of mRNA cell engineering, CEO Matt Angel said in a statement.
Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in regulatory, compliance and data protection functions. Before that, she was an attorney representing pharmaceutical companies and healthcare organizations, the company said.
“I believe Eterna’s mRNA cell engineering platform holds significant potential for collaborative opportunities, and look forward to working with the leadership team and my fellow Board members to advance Eterna’s growth and corporate strategy,” Ms. Clarke said.